ArticleTranslational andrology and urology2025
A new surgical method of vasoepididymostomy for epididymal obstructive azoospermia to improve the success rate in the rat.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Two-suture longitudinal intussusception vasoepididymostomy (LIVE) surgery has been confirmed by many studies in the treatment of epididymal obstruction; however, the success rate and anastomotic patency rate are not high, which cannot meet the modern human demand for a cure rate for this disease. Based on our preliminary research, we have reason to speculate that the new 2-suture circular intussusception vasoepididymostomy (CIVE) surgery group can greatly improve the anastomosis rate and success rate of treating epididymal obstruction patients. LIVE has become the preferred technique for epididymal and vas deferens anastomosis in North America, Europe, and globally for 22 years. Compared with LIVE, CIVE can greatly improve the anastomosis and success rate of treating epididymal obstruction patients. The aim of this study is to make CIVE the preferred technique for treating epididymal obstruction in North America, Europe, and globally. CIVE ultimately benefits more patients. Methods: Thirty-three male rats (type: Sprague-Dawley, SD) were randomly divided into control (group I) and experimental groups (groups II and III). After 3 weeks of epididymal obstruction, bilateral vasoepididymostomy was performed. In group II, the epididymal tubules (the epididymal tubules, which were cut into circular incisions) were punctured and lifted with a suture under a microscope, the vas deferens was incised obliquely at 45° for CIVE. In group III: LIVE was performed. After 3 months, patency was assessed in a blinded manner. Results: The rates of functional patency (presence of motile sperm in the vas deferens) were 90.9% and 63.6% in groups II and III, respectively (single-tailed test, P=0.042). On retrograde methylene blue vasography of the epididymis, the mechanical patency rate was similar to the functional patency rate. The incidence of sperm granulomas in postoperative groups II and III was 0% and 18.2%, respectively, with a single-tailed test P value of 0.24. Due to insufficient sample size, the sample size can be expanded for further verification in the later stage. Conclusions: Compared with LIVE, CIVE at a 45° oblique incision of the vas deferens provides a larger anastomotic area and has a higher recanalization rate, which is worthy of further investigation. The aim of this study is to propose a new surgical approach called 'CIVE'. By expanding the anastomotic area to reduce the risk of traditional surgical failure, the ultimate goal is to provide patients with safer and more efficient treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.